Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 24, 2022, details the entry into a Material Definitive Agreement by Evolent Health, Inc. (EVH) and its subsidiary, Evolent Health LLC. The agreement outlines a merger with TPG Growth Iceman Parent, Inc., the parent entity of Implantable Provider Group, Inc. The transaction is structured to close on the second business day following the satisfaction of conditions, but no earlier than August 1, 2022.
Key Financial Metrics and Transaction Structure
The filing does not provide standard operating financial metrics such as revenue, profit, or cash flow for the reporting period. Instead, it details the financial terms of the proposed acquisition:
- Total Merger Consideration: Approximately $375 million in base value, subject to adjustments.
- Cash Consideration: $250,000,000.
- Equity Consideration: Shares of EVH Class A Common Stock valued at $125,000,000 (based on a 10-day VWAP prior to closing).
- Earnout Consideration: Up to $87,000,000 contingent on operating results for the periods ending December 31, 2022, and the first three quarters of 2023.
- Debt Financing: EVH LLC secured a commitment for $225,000,000 in secured debt from Ares Capital Management LLC to fund the cash portion.
- Termination Fee: $30,000,000 payable to the Company/Seller Parties under specific termination scenarios.
Material Changes and Financing Details
The primary material change is the execution of the Merger Agreement. To finance the transaction, EVH LLC entered into a debt financing commitment letter with Ares Capital Management LLC. The $225 million facility is structured as:
- Term Loan: Up to $175,000,000 at an initial rate of adjusted term SOFR plus 5.50%.
- Revolving Credit Facility: Up to $50,000,000 at an initial rate of adjusted term SOFR plus 3.50%.
- Maturity: The earlier of five years from the Closing Date or 91 days prior to the earliest maturity of other secured indebtedness.
Additionally, a Purchase Price Adjustment Agreement will escrow 15% of the Equity Consideration value to manage market fluctuations over the 90 days following closing.
Guidance, Risks, and Contingencies
The transaction is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period, the absence of legal impediments, and the accuracy of representations and warranties. The filing includes standard forward-looking statements regarding the consummation of the merger and receipt of financing, noting that actual results may differ materially due to risks such as litigation or regulatory delays. The Merger Agreement may be terminated by mutual consent, breach of covenants, or if the closing does not occur by December 31, 2022.
Key Facts for Investor Verification
- Verify the final closing date and whether the August 1, 2022, earliest closing date is met.
- Monitor the volume-weighted average price (VWAP) of EVH Class A shares to determine the final number of shares issued for the $125 million equity portion.
- Track the Company's operating results for the earnout periods (Aug 1, 2022 – Dec 31, 2022, and Q1-Q3 2023) to assess the potential $87 million earnout payout.
- Confirm the final terms and funding of the $225 million debt facility with Ares Capital Management LLC.
- Review the escrow release conditions related to the 15% equity value held in the Purchase Price Adjustment Agreement.